Results 191 to 200 of about 216,697 (311)

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Cardiac Arrhythmias

open access: yesJournal of the American College of Cardiology, 2006
openaire   +3 more sources

Predicting 1‐year heart failure hospitalization and mortality post‐discharge from the intensive cardiac care unit

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Despite the high risk of rehospitalization for heart failure (HF) and death among patients admitted to the intensive cardiac care unit (ICCU), no accurate prediction score for these outcomes exists. We aimed to develop a risk score to predict unplanned HF hospitalization and death 1‐year post‐discharge in an unselected cohort of patients ...
Andreas Bugge Tinggaard   +116 more
wiley   +1 more source

Cardiac arrhythmias

open access: yesJournal of the American College of Cardiology, 2004
openaire   +3 more sources

Clinical and Genetic Findings in Children Presenting With Ventricular Fibrillation as the First Manifestation of Cardiovascular Disease

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Robyn J. Hylind   +9 more
doaj   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy